Zhengye Biotechnology Holding Limited (ZYBT)
Healthcare
- Fundamental
- 1
- Sentiment
- 3
- Technical
- 3
Do Nothing: fundamentalScore is 1 (below required floor of 3); additionally, max overnight gap is 68.21% and recent 3-session regular-session dollar volume averages only $1,614.42, so the tape is untradeable for this strategy.
Company overview
Zhengye Biotechnology Holding Limited develops and markets animal health vaccines, primarily serving the Chinese agricultural sector. The company offers vaccines for a variety of farm animals and also exports to countries like Vietnam, Pakistan, and Egypt. It operates as a subsidiary of Securingium Holding Limited, with headquarters in Jilin, China.
Fundamental
very weakZhengye Biotechnology's fundamentals are weak with significant revenue decline and profitability loss in FY2025.
Too risky: FY2025 revenue fell 37.56% and profitability swung to a deep loss (net margin -59.97%, EBITDA margin -36.54%). SEC filings highlight PRC regulatory/controls risks plus a Nasdaq $1 minimum bid-price deficiency notice (deadline 2026-11-25). With an extremely low free float (~9%) and discounted-cash-flow outputs far below the current price, the risk/reward is unfavorable.
Sentiment
fairRetail momentum is high, but there's no substantial media coverage or clear catalysts.
ZYBT’s near-term action looks driven by a same-day retail/momentum burst (Reddit posts flagging extreme RVOL and large % moves; confidence: rumored) while mainstream news flow in the last ~14 days is effectively absent, making the sentiment delta indeterminate. The unresolved Nasdaq minimum-bid-price deficiency (announced 2026-06-04) adds a bearish overhang that conflicts with the bullish tape, so the setup is capped at 3 on the Red-Flag Screen (mixed/conflicting signals + promotional chatter).
Technical
fairThe stock experienced a sharp price increase, but technical indicators suggest it's overbought.
Price exploded above SMA20/50/200 and EMA9/21 with MACD turning strongly positive and ADX14 at 31.99, but RSI14 93.34 and Williams %R -3.15 show a severely stretched one-day squeeze rather than a stable low-risk continuation base.
You’re looking at 2026-07-20 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.